# Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

> **NCT00059787** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (actual)

## Conditions studied

- Brenner Tumor
- Fallopian Tube Cancer
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Ovarian Undifferentiated Adenocarcinoma
- Stage III Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer

## Interventions

- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT00059787
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2015-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00059787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00059787, "Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00059787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*